| San Juan Center | |
| 806 West Maple Street, Farmington, New Mexico 87401 | |
| (505) 325-2910 | |
| Name | San Juan Center |
|---|---|
| Location | 806 West Maple Street, Farmington, New Mexico |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 93 |
| Occupancy Rate | 86.88% |
| Medicare ID (CCN) | 325085 |
| Legal Business Name | Peak Medical Farmington Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1124702246 |
| Organization Name | SAN JUAN CARE CENTER LLC |
| Address | 806 W Maple St, Farmington, NM 87401 |
| Phone Number | 505-325-2910 |
News Archive
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
A unique 21-year study of more than 2.4 million cases of infectious disease across Australia reveals a major social divide where being poorer, living remotely or being an Indigenous Australian means having an increased risk of sexually transmissible infections (STIs).
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
The Trump administration's watershed decision Thursday to allow states to test a work requirement for adult Medicaid enrollees sparked widespread criticism from doctors, advocates for the poor, and minority and disability rights groups.
› Verified 1 days ago
| NPI Number | 1942255880 |
| Organization Name | PEAK MEDICAL FARMINGTON, LLC |
| Doing Business As | SAN JUAN CENTER |
| Address | 806 W Maple St, Farmington, NM 87401 |
| Phone Number | 505-325-2910 |
News Archive
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
A unique 21-year study of more than 2.4 million cases of infectious disease across Australia reveals a major social divide where being poorer, living remotely or being an Indigenous Australian means having an increased risk of sexually transmissible infections (STIs).
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
The Trump administration's watershed decision Thursday to allow states to test a work requirement for adult Medicaid enrollees sparked widespread criticism from doctors, advocates for the poor, and minority and disability rights groups.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
A unique 21-year study of more than 2.4 million cases of infectious disease across Australia reveals a major social divide where being poorer, living remotely or being an Indigenous Australian means having an increased risk of sexually transmissible infections (STIs).
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
The Trump administration's watershed decision Thursday to allow states to test a work requirement for adult Medicaid enrollees sparked widespread criticism from doctors, advocates for the poor, and minority and disability rights groups.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 8.06 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 39.34 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.47 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.38 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 6.06 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 80 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 9.75 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 6.53 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.19 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 73.87 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 77.1 | 82.93 |
News Archive
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
A unique 21-year study of more than 2.4 million cases of infectious disease across Australia reveals a major social divide where being poorer, living remotely or being an Indigenous Australian means having an increased risk of sexually transmissible infections (STIs).
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
The Trump administration's watershed decision Thursday to allow states to test a work requirement for adult Medicaid enrollees sparked widespread criticism from doctors, advocates for the poor, and minority and disability rights groups.
› Verified 1 days ago
Life Care Center Of Farmington Location: 1101 West Murray Drive, Farmington, New Mexico 87401 Phone: (505) 326-1600 | |
Welbrook Senior Living, Llc Location: 201 Nelson Avenue, Farmington, New Mexico 87401 Phone: (505) 675-4545 |